{"id":71385,"date":"2026-07-30T20:29:57","date_gmt":"2026-07-30T12:29:57","guid":{"rendered":"https:\/\/flcube.com\/?p=71385"},"modified":"2026-07-30T20:29:59","modified_gmt":"2026-07-30T12:29:59","slug":"hengrui-pharmaceuticals-secures-nmpa-approval-for-hrs5580-long-acting-nk-1-antagonist-in-combination-therapy-for-postoperative-nausea-and-vomiting-prevention","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71385","title":{"rendered":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that its novel <strong>selective neurokinin-1 (NK-1) receptor antagonist HRS5580<\/strong> has received <strong>clinical trial approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for the <strong>prevention of postoperative nausea and vomiting (PONV)<\/strong> in combination with <strong>palonosetron hydrochloride injection<\/strong>. HRS5580 represents a potential <strong>first-in-class long-acting NK-1 antagonist formulation<\/strong>, addressing a significant gap in the current antiemetic market landscape.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval for combination therapy<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HRS5580 (NK-1 receptor antagonist) + palonosetron hydrochloride<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of postoperative nausea and vomiting (PONV)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Clinical trial initiation approved<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (dual-listed: SHA 600276, HKG 1276)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-competitive-differentiation\" class=\"wp-block-heading\">Drug Profile &amp; Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> <strong>Selective NK-1 receptor antagonist<\/strong> that blocks substance P binding with high affinity, providing potent antiemetic effects through central nervous system pathway modulation<\/li>\n\n\n\n<li><strong>Key Advantages:<\/strong><\/li>\n\n\n\n<li><strong>High solubility<\/strong> enabling favorable formulation characteristics<\/li>\n\n\n\n<li><strong>Long-acting efficacy<\/strong> \u2013 potentially first long-acting NK-1 antagonist in development<\/li>\n\n\n\n<li><strong>Favorable safety profile<\/strong> based on preclinical and early clinical data<\/li>\n\n\n\n<li><strong>Market Gap:<\/strong> Current approved NK-1 antagonists like <strong>Heron Therapeutics&#8217; aprepitant injectable emulsion (APONVIE)<\/strong> are <strong>short-acting formulations<\/strong>, creating opportunity for extended-duration therapy<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Paired with <strong>palonosetron<\/strong> (5-HT3 antagonist) to provide comprehensive multi-pathway PONV prevention covering both acute and delayed phases<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-clinical-need\" class=\"wp-block-heading\">Market Opportunity &amp; Clinical Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Postoperative nausea and vomiting<\/strong> affects <strong>30-80% of surgical patients<\/strong> depending on risk factors, representing one of the most common and distressing postoperative complications. The <strong>global PONV therapeutics market<\/strong> is valued at approximately <strong>$2.5 billion annually<\/strong>, with combination therapies increasingly becoming standard of care for moderate-to-high risk patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current treatment limitations include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Short duration of action<\/strong> requiring multiple doses or continuous infusion<\/li>\n\n\n\n<li><strong>Suboptimal efficacy<\/strong> in high-risk patient populations<\/li>\n\n\n\n<li><strong>Formulation challenges<\/strong> limiting administration flexibility<\/li>\n\n\n\n<li><strong>Incomplete coverage<\/strong> of both acute (0-24 hours) and delayed (24-120 hours) PONV phases<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">HRS5580&#8217;s <strong>long-acting profile<\/strong> could enable <strong>single-dose administration<\/strong> with sustained protection throughout the critical postoperative period, potentially improving patient outcomes and reducing healthcare resource utilization.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Hengrui:<\/strong> Expands oncology-focused portfolio into <strong>perioperative care market<\/strong>, diversifying revenue streams beyond cancer therapeutics<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Potential <strong>first-mover advantage<\/strong> in long-acting NK-1 antagonist segment with significant differentiation from existing short-acting competitors<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Success in Chinese market could support <strong>international regulatory filings<\/strong> and partnership opportunities with global pharmaceutical companies<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Leverage Hengrui&#8217;s established hospital sales force and perioperative care relationships for rapid market penetration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps\" class=\"wp-block-heading\">Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Trial Design:<\/strong> Phase II\/III study evaluating <strong>efficacy and safety<\/strong> of HRS5580-palonosetron combination versus standard of care<\/li>\n\n\n\n<li><strong>Primary Endpoints:<\/strong> Complete response rate (no emesis, no rescue medication) during 0-120 hour postoperative period<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Potential for <strong>accelerated approval<\/strong> based on unmet need and differentiated profile<\/li>\n\n\n\n<li><strong>Manufacturing Scale-up:<\/strong> Prepare commercial-scale production capabilities pending successful clinical outcomes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive developments, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260730_P9R8.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260730_P9R8.\"><\/object><a id=\"wp-block-file--media-55aafb6a-8658-434b-9ce6-e96cb5c12a44\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260730_P9R8.pdf\">600276_20260730_P9R8<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260730_P9R8.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-55aafb6a-8658-434b-9ce6-e96cb5c12a44\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,2586,4228,852],"class_list":["post-71385","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1 (NK-1) receptor antagonist HRS5580 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the prevention of postoperative nausea and vomiting (PONV) in combination with palonosetron hydrochloride injection. HRS5580 represents a potential first-in-class long-acting NK-1 antagonist formulation, addressing a significant gap in the current antiemetic market landscape.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71385\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1 (NK-1) receptor antagonist HRS5580 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the prevention of postoperative nausea and vomiting (PONV) in combination with palonosetron hydrochloride injection. HRS5580 represents a potential first-in-class long-acting NK-1 antagonist formulation, addressing a significant gap in the current antiemetic market landscape.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71385\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T12:29:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T12:29:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71385#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71385\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention\",\"datePublished\":\"2026-07-30T12:29:57+00:00\",\"dateModified\":\"2026-07-30T12:29:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71385\"},\"wordCount\":508,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71385#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71385\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71385\",\"name\":\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-30T12:29:57+00:00\",\"dateModified\":\"2026-07-30T12:29:59+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1 (NK-1) receptor antagonist HRS5580 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the prevention of postoperative nausea and vomiting (PONV) in combination with palonosetron hydrochloride injection. HRS5580 represents a potential first-in-class long-acting NK-1 antagonist formulation, addressing a significant gap in the current antiemetic market landscape.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71385#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71385\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71385#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1 (NK-1) receptor antagonist HRS5580 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the prevention of postoperative nausea and vomiting (PONV) in combination with palonosetron hydrochloride injection. HRS5580 represents a potential first-in-class long-acting NK-1 antagonist formulation, addressing a significant gap in the current antiemetic market landscape.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71385","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1 (NK-1) receptor antagonist HRS5580 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the prevention of postoperative nausea and vomiting (PONV) in combination with palonosetron hydrochloride injection. HRS5580 represents a potential first-in-class long-acting NK-1 antagonist formulation, addressing a significant gap in the current antiemetic market landscape.","og_url":"https:\/\/flcube.com\/?p=71385","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-30T12:29:57+00:00","article_modified_time":"2026-07-30T12:29:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71385#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71385"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention","datePublished":"2026-07-30T12:29:57+00:00","dateModified":"2026-07-30T12:29:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71385"},"wordCount":508,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71385#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71385","url":"https:\/\/flcube.com\/?p=71385","name":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-30T12:29:57+00:00","dateModified":"2026-07-30T12:29:59+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1 (NK-1) receptor antagonist HRS5580 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the prevention of postoperative nausea and vomiting (PONV) in combination with palonosetron hydrochloride injection. HRS5580 represents a potential first-in-class long-acting NK-1 antagonist formulation, addressing a significant gap in the current antiemetic market landscape.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71385#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71385"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71385#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71385"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71385\/revisions"}],"predecessor-version":[{"id":71387,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71385\/revisions\/71387"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}